Anti-CD19 Anti-CD3 Bispecific Monoclonal Antibody

Cancer Terms -> Drugs and Chemicals -> Pharmacologic Substance -> Biological Response Modifier -> Bispecific Antibody -> Anti-CD19 Anti-CD3 Bispecific Monoclonal Antibody

Anti-CD19 Anti-CD3 Bispecific Monoclonal Antibody Definition

A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.

Anti-CD19 Anti-CD3 Bispecific Monoclonal Antibody Synonyms

Blinatumomab, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, MEDI-538, MT-103

Terms in Anti-CD19 Anti-CD3 Bispecific Monoclonal Antibody category

---

Copyright © Cancer Terms 2014 All rights reserved. | Terms of Use | Low Carb Foods
No reproduction or republication permitted.